Literature DB >> 16828972

Expression of recombinant human antibody fragments capable of inhibiting the phospholipase and myotoxic activities of Bothrops jararacussu venom.

M B Tamarozzi1, S G Soares, S Marcussi, J R Giglio, J E Barbosa.   

Abstract

Phospholipases A(2) are components of Bothrops venoms responsible for disruption of cell membrane integrity via hydrolysis of its phospholipids. This study used a large nonimmune human scFv library named Griffin.1 (MRC, Cambridge, UK) for selection of recombinant antibodies against antigens present in Bothrops jararacussu venom and identification of specific antibodies able to inhibit phospholipase activity. Four clones were identified as capable of inhibiting this activity in vitro. These clones were able to reduce in vivo the myotoxic activity of BthTX-I and BthTX-II PLA(2), but had no effect on the in vitro anticoagulant activity of BthTX-II. This work shows the potential of using recombinant scFv libraries in the search for antibodies that neutralize relevant venom components.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828972     DOI: 10.1016/j.bbagen.2006.04.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

Review 1.  History of Envenoming Therapy and Current Perspectives.

Authors:  Manuela B Pucca; Felipe A Cerni; Rahel Janke; Erick Bermúdez-Méndez; Line Ledsgaard; José E Barbosa; Andreas H Laustsen
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

2.  Bibliometric Analysis of Literature in Snake Venom-Related Research Worldwide (1933-2022).

Authors:  Fajar Sofyantoro; Donan Satria Yudha; Kenny Lischer; Tri Rini Nuringtyas; Wahyu Aristyaning Putri; Wisnu Ananta Kusuma; Yekti Asih Purwestri; Respati Tri Swasono
Journal:  Animals (Basel)       Date:  2022-08-12       Impact factor: 3.231

Review 3.  Recent Advances in Next Generation Snakebite Antivenoms.

Authors:  Cecilie Knudsen; Andreas H Laustsen
Journal:  Trop Med Infect Dis       Date:  2018-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.